全球首个！上海AI制药新融资，英矽智能投了！

TL;DR - Byterna Therapeutics raised tens of millions of yuan in Pre-A funding to advance AI-designed circular mRNA therapies, including an in vivo CAR-T candidate and personalized cancer vaccines.

• Funds will support a clinical filing for a dual-target circular mRNA in vivo CAR-T therapy currently in an investigator-initiated trial.
• Byterna applies AI to neoantigen prediction and sequence design for personalized circular mRNA cancer vaccines.
• The company and investor Insilico Medicine plan to build an AI-native R&D engine spanning circular mRNA design through clinical translation.
• The platform combines AI design, circular mRNA, and targeted lipid nanoparticle delivery.